エリスロポエチン製剤の世界市場 - 2025年～2032年

エリスロポエチン製剤の世界市場は2024年に107億7,000万米ドルに達し、そして2032年には145億9,000万米ドルに達すると予測され、予測期間2025年のCAGRは7.9％です。

エリスロポエチン製剤は、天然に存在するホルモンであるエリスロポエチン（EPO）の合成型であり、主に腎臓で産生されます。EPOは、骨髄における赤血球産生、特に血液中の低酸素レベルに対応する赤血球産生の調節において重要な役割を果たしています。これらの薬剤は主に貧血の治療に使用され、特に慢性腎臓病を患っている患者、がんの化学療法を受けている患者、または体内で十分な赤血球を産生する能力を妨げているその他の疾患を持つ患者に使用されます。

赤血球前駆細胞の分化と増殖を刺激することにより、エリスロポエチン製剤は赤血球数を効果的に増加させ、疲労や脱力感などの貧血に伴う症状を緩和するのに役立ちます。

市場力学：

促進要因と抑制要因

貧血の有病率の増加

特に慢性腎臓病（CKD）やがんなどの慢性疾患によって引き起こされる貧血の有病率の増加が、エリスロポエチン製剤市場の成長を大きく後押ししています。腎機能低下は赤血球形成に不可欠なエリスロポエチンの産生低下につながるため、貧血はCKD患者によく見られる合併症です。例えば、2024年の米国国立衛生研究所の報告によると、CKDの貧血は通常、GFRが60mL/分/1.73m2を下回ると発症し、ステージ3のCKD患者の最大20％が貧血を示します。透析依存となった患者の少なくとも90％が最終的に貧血を発症します。

人口の高齢化、食生活の変化、CKDのような疾患の有病率の増加などの要因により、世界的に貧血患者が増加しており、エリスロポエチンをベースとした薬剤のような効果的な治療に対するニーズが高まっています。

さらに、がん治療、特に化学療法は、骨髄機能に影響を与えるため、しばしば貧血を引き起こします。CKDやがんと診断される患者数が世界的に増加し続ける中、赤血球産生を促進し貧血に伴う症状を緩和するために重要なエリスロポエチン製剤の需要が増加しています。

エリスロポエチン製剤に関連する副作用と安全性の懸念

エリスロポエチン製剤に関連する副作用と安全性の懸念がエリスロポエチン製剤市場の妨げとなっています。EPO製剤は貧血治療に有効であるが、使い過ぎると深刻な副作用を引き起こす可能性があります。これには、高血圧、心臓発作や脳卒中などの心血管系イベント、血栓塞栓イベントが含まれます。場合によっては、EPO製剤が血栓のリスクを高めたり、基礎にある心臓の状態を悪化させたりして、深刻な健康合併症を引き起こすこともあります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 貧血の罹患率の増加
  • 抑制要因
    • エリスロポエチン製剤に関連する副作用と安全性の懸念
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 タイプ別

• 生物学的製剤
• バイオシミラー

第7章 薬の種類別

• エポエチンアルファ
• エポエチンベータ
• エポエチンゼータ
• エポエチンオメガ
• ダルベポエチンアルファ
• その他

第8章 投与経路別

• 経口
• 非経口

第9章 適応症別

• がん
• 腎臓疾患
• 血液疾患
• その他

第10章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第12章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第13章 企業プロファイル

• Pfizer Inc.
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Amgen Inc.
• Johnson & Johnson Services, Inc.
• F. Hoffmann-La Roche Ltd
• Dr. Reddy's Laboratories Ltd.
• Intas Pharmaceuticals
• Akron Biotech
• Sandoz Group AG
• ratiopharm GmbH
• Biocon Limited

第14章 付録

The global erythropoietin drugs market reached US$ 10.77 billion in 2024 and is expected to reach US$ 14.59 billion by 2032, growing at a CAGR of 7.9% during the forecast period 2025-2032.

Erythropoietin drugs are synthetic forms of the naturally occurring hormone erythropoietin (EPO), which is primarily produced by the kidneys. EPO plays a crucial role in regulating red blood cell production in the bone marrow, particularly in response to low oxygen levels in the blood. These drugs are primarily employed to treat anemia, especially in patients suffering from chronic kidney disease, those undergoing chemotherapy for cancer, or individuals with other conditions that hinder the body's ability to produce adequate red blood cells.

By stimulating the differentiation and proliferation of erythroid progenitor cells, erythropoietin drugs effectively increase red blood cell counts, which helps alleviate symptoms associated with anemia, such as fatigue and weakness.

Market Dynamics: Drivers & Restraints

Increasing prevalence of anemia

The increasing prevalence of anemia, particularly driven by chronic diseases such as chronic kidney disease (CKD) and cancer, is significantly propelling the growth of the erythropoietin drugs market. Anemia is a common complication in patients with CKD, as impaired kidney function leads to reduced production of erythropoietin, which is essential for red blood cell formation. For instance, according to the report by the National Institute of Health in 2024, Anemia of CKD typically develops when the GFR falls below 60 mL/min/1.73 m2, with up to 20% of patients at stage 3 CKD demonstrating anemia. At least 90% of patients who become dialysis-dependent will eventually develop anemia.

With the rising global anemia patients, driven by factors like aging populations, dietary changes, and the growing prevalence of diseases such as CKD, there is a growing need for effective treatments like erythropoietin-based drugs.

Additionally, cancer treatments, especially chemotherapy, often result in anemia due to their impact on bone marrow function. As the number of individuals diagnosed with CKD and cancer continues to rise globally, the demand for erythropoietin drugs increases, which are critical for stimulating red blood cell production and alleviating symptoms associated with anemia.

Adverse effects and safety concerns associated with erythropoietin drugs

The adverse effects associated with the erythropoietin drugs and the safety concerns associated are hindering the erythropoietin drugs market. While EPO drugs are effective in treating anemia, their overuse can lead to serious side effects. These include hypertension, cardiovascular events such as heart attacks or strokes, and thromboembolic events. In some cases, EPO drugs can increase the risk of blood clots or worsen underlying heart conditions, leading to severe health complications.

Segment Analysis

The global erythropoietin drugs market is segmented based on drug type, indication, route of administration, distribution channel, end-user, and region.

Drug Type:

Epoetin alfa segment is expected to dominate the global erythropoietin drugs market share

The epoetin alfa segment is anticipated to lead the erythropoietin (EPO) drugs market due to its proven efficacy, widespread use, and cost-effectiveness. Epoetin alfa is primarily prescribed to treat anemia related to chronic kidney disease (CKD), chemotherapy, and other conditions. Its long-standing track of safety and effectiveness makes it a preferred choice for healthcare professionals in managing anemia.

The extensive clinical experience with epoetin alfa has resulted in its strong market presence, particularly in regions with well-developed healthcare systems. Additionally, the availability of both branded and biosimilar versions of epoetin alfa is allowing it to an accessible to a broader patient population.

Biosimilars, being more affordable alternatives to the original drug, have gained popularity and helped expand the reach of epoetin alfa therapies. The combination of these affordable biosimilars and the increasing prevalence of anemia, especially in conditions like CKD, is expected to further strengthen the dominance of the epoetin alfa segment in the EPO drugs market.

Geographical Analysis

North America is expected to hold a significant position in the global erythropoietin drugs market share

North America is expected to hold a significant position in the erythropoietin (EPO) drugs market. The region's growth is driven by the incidence of anemia, a robust healthcare system, and ongoing advancements in medical research and treatment options. The region has a significant number of people suffering from chronic diseases such as chronic kidney disease (CKD), cancer, and diabetes, which are major contributors to anemia. For instance, according to the Centers for Disease Control and Prevention in 2024, more than 1 in 7 US adults, about 35.5 million people, or 14% are estimated to have CKD. This incidence is expected to increase the occurrence of anemia. As the prevalence of these conditions rises, the demand for effective treatments like erythropoietin drugs, which stimulate the production of red blood cells to address anemia, continues to grow.

Pharmaceutical companies, especially those located in the U.S. and Canada, are leading the way in the research and development of erythropoietin therapies. The presence of several pharmaceutical companies in the region is leading to the innovation of advanced and more effective drug formulations for managing anemia. For instance, In February 2023, GSK plc received the US Food and Drug Administration (FDA) approval for Jesduvroq (daprodustat), for the once-a-day treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months.

Jesduvroq is the first innovative medicine for anemia treatment in over 30 years and the only HIF-PHI approved in the US, providing a new oral, convenient option for patients in the US with anemia of CKD on dialysis.

Furthermore, the increasing awareness of anemia and its related conditions, coupled with the demonstrated effectiveness of EPO drugs, is driving greater demand in North America. These combined factors are positioning North America as a major player in the global erythropoietin drugs market.

Competitive Landscape

The major global players in the erythropoietin drugs market include Dr. Reddy's Laboratories Ltd., Otsuka Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Alkermes, Eli Lilly and Company, Bristol-Myers Squibb Company, Sumitomo Pharma Co., Ltd. and Pfizer Inc. among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Erythropoietin Drugs market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Drug Type
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Route of Indication
• 3.5. Snippet by Distribution Channel
• 3.6. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing prevalence of anemia
  • 4.1.2. Restraints
    • 4.1.2.1. Adverse effects and safety concerns associated with erythropoietin drugs
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Biologics*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Biosimilars

7. By Drug Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 7.1.2. Market Attractiveness Index, By Drug Type
• 7.2. Epoetin alfa*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Epoetin beta
• 7.4. Epoetin zeta
• 7.5. Epoetin omega
• 7.6. Darbepoetin alfa
• 7.7. Others

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Oral*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Parenteral

9. By Indication

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 9.1.2. Market Attractiveness Index, By Indication
• 9.2. Cancer*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Renal Diseases
• 9.4. Hematological Disorders
• 9.5. Others

10. By Distribution Channel

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.1.2. Market Attractiveness Index, By Distribution Channel
• 10.2. Hospital Pharmacies*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Retail Pharmacies
• 10.4. Online Pharmacies

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.8.1. U.S.
    • 11.2.8.2. Canada
    • 11.2.8.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.8.1. Germany
    • 11.3.8.2. U.K.
    • 11.3.8.3. France
    • 11.3.8.4. Spain
    • 11.3.8.5. Italy
    • 11.3.8.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.8.1. Brazil
    • 11.4.8.2. Argentina
    • 11.4.8.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.8.1. China
    • 11.5.8.2. India
    • 11.5.8.3. Japan
    • 11.5.8.4. South Korea
    • 11.5.8.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Pfizer Inc.*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Amgen Inc.
• 13.3. Johnson & Johnson Services, Inc.
• 13.4. F. Hoffmann-La Roche Ltd
• 13.5. Dr. Reddy's Laboratories Ltd.
• 13.6. Intas Pharmaceuticals
• 13.7. Akron Biotech
• 13.8. Sandoz Group AG
• 13.9. ratiopharm GmbH
• 13.10. Biocon Limited

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us